SG11201401021TA - Pyrrolobenzodiazepines - Google Patents
PyrrolobenzodiazepinesInfo
- Publication number
- SG11201401021TA SG11201401021TA SG11201401021TA SG11201401021TA SG11201401021TA SG 11201401021T A SG11201401021T A SG 11201401021TA SG 11201401021T A SG11201401021T A SG 11201401021TA SG 11201401021T A SG11201401021T A SG 11201401021TA SG 11201401021T A SG11201401021T A SG 11201401021TA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrrolobenzodiazepines
- Prior art date
Links
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547198P | 2011-10-14 | 2011-10-14 | |
| PCT/EP2012/070233 WO2013053873A1 (en) | 2011-10-14 | 2012-10-12 | Pyrrolobenzodiazepines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401021TA true SG11201401021TA (en) | 2014-08-28 |
Family
ID=47019020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401021TA SG11201401021TA (en) | 2011-10-14 | 2012-10-12 | Pyrrolobenzodiazepines |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9399073B2 (enExample) |
| EP (1) | EP2751111B1 (enExample) |
| JP (1) | JP6170497B2 (enExample) |
| KR (1) | KR101891859B1 (enExample) |
| CN (1) | CN103998450B (enExample) |
| AU (1) | AU2012322934B2 (enExample) |
| BR (1) | BR112014008888A2 (enExample) |
| CA (1) | CA2850103C (enExample) |
| EA (1) | EA028457B1 (enExample) |
| MX (1) | MX341523B (enExample) |
| SG (1) | SG11201401021TA (enExample) |
| WO (1) | WO2013053873A1 (enExample) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| CN103987718A (zh) | 2011-09-20 | 2014-08-13 | 斯皮罗根有限公司 | 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓 |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CN103998450B (zh) | 2011-10-14 | 2017-03-08 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓 |
| CN103998449A (zh) | 2011-10-14 | 2014-08-20 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓 |
| HRP20180945T1 (hr) | 2012-10-12 | 2018-08-10 | Adc Therapeutics Sa | Konjugati protutijelo-pirolobenzodiazepin |
| PT2906253T (pt) | 2012-10-12 | 2018-11-05 | Medimmune Ltd | Conjugados de anticorpo anti-psma de pirrolobenzodiazepina |
| CA2885305C (en) | 2012-10-12 | 2019-11-12 | Spirogen Sarl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| LT2906251T (lt) | 2012-10-12 | 2017-12-11 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-cd22 antikūno konjugatai |
| RS58921B1 (sr) | 2012-10-12 | 2019-08-30 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
| CN104703630A (zh) | 2012-10-12 | 2015-06-10 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| HRP20182129T1 (hr) | 2012-10-12 | 2019-02-08 | Adc Therapeutics Sa | Konjugati protutijelo - pirolobenzodiazepin |
| WO2014096368A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| JP6527466B2 (ja) | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
| HK1220698A1 (zh) | 2013-03-13 | 2017-05-12 | Seattle Genetics, Inc. | 环糊精和抗体药物偶联物制剂 |
| US9453046B2 (en) | 2013-03-13 | 2016-09-27 | Seattle Genetics, Inc. | Activated carbon filtration for purification of benzodiazepine ADCs |
| WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| NZ710746A (en) | 2013-03-13 | 2018-11-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP2968593B1 (en) | 2013-03-15 | 2024-11-20 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| MX373528B (es) | 2013-08-26 | 2020-04-21 | Regeneron Pharma | Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos. |
| MX2016002545A (es) * | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso. |
| KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
| RU2016111139A (ru) | 2013-08-28 | 2017-10-03 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые модуляторы sez6 и способы их применения |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| JP6747971B2 (ja) | 2013-10-15 | 2020-08-26 | シアトル ジェネティックス， インコーポレイテッド | 改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー |
| CN103641834B (zh) * | 2013-12-12 | 2015-12-09 | 沈阳药科大学 | 吡咯并苯并二氮杂*类化合物及其制备方法和应用 |
| JP6681838B2 (ja) * | 2013-12-16 | 2020-04-15 | ジェネンテック， インコーポレイテッド | ペプチド模倣薬化合物及びその抗体−薬剤複合体 |
| IL290330B2 (en) | 2013-12-19 | 2023-09-01 | Seagen Inc | Methylene carbamate binders for use with drug-targeting conjugates |
| CA2939941A1 (en) | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| RS59077B1 (sr) | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antitela i njihova primena |
| CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| PL3191135T3 (pl) | 2014-09-12 | 2021-01-25 | Genentech, Inc. | Przeciwciała i immunokoniugaty anty-HER2 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| KR20170101895A (ko) | 2014-11-25 | 2017-09-06 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 접합체 |
| JP6676058B2 (ja) | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| JP6498773B2 (ja) | 2015-01-14 | 2019-04-10 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| SG11201707148PA (en) | 2015-03-27 | 2017-10-30 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| MX2017015814A (es) | 2015-06-23 | 2018-04-10 | Squibb Bristol Myers Co | Dimeros de benzodiazepina macrociclica, conjugados de los mismos, preparacion y usos. |
| EP3319994B1 (en) | 2015-07-06 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| EP3387017A1 (en) | 2015-12-11 | 2018-10-17 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
| CN108779127B (zh) | 2016-01-25 | 2022-07-05 | 里珍纳龙药品有限公司 | 美登素类化合物衍生物、其偶联物和使用方法 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017201132A2 (en) | 2016-05-18 | 2017-11-23 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| JP7049276B2 (ja) | 2016-06-24 | 2022-04-06 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピンおよびその結合体 |
| US20190328900A1 (en) | 2016-07-01 | 2019-10-31 | Glaxosmithkline Intellectual Property Development Limited | Antibody-drug conjugates and therapeutic methods using the same |
| EP3515487B1 (en) | 2016-09-23 | 2023-07-19 | Regeneron Pharmaceuticals, Inc. | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
| JP7078609B2 (ja) | 2016-09-23 | 2022-05-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｓｔｅａｐ２抗体、抗体－薬物複合体、およびｓｔｅａｐ２とｃｄ３を結合する二重特異性抗原結合分子、ならびにそれらの使用 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| JP7330101B2 (ja) | 2016-11-08 | 2023-08-21 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ステロイド及びそのタンパク質コンジュゲート |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| SI3544636T1 (sl) | 2017-02-08 | 2021-08-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| CN110430901B (zh) | 2017-03-24 | 2024-08-16 | 西雅图基因公司 | 制备葡糖苷酸药物-接头及其中间体的方法 |
| HRP20221063T1 (hr) | 2017-04-18 | 2022-11-11 | Medimmune Limited | Konjugati pirolobenzodiazepina |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
| MA47392B1 (fr) | 2017-05-18 | 2021-09-30 | Regeneron Pharma | Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques |
| CA3066569A1 (en) | 2017-06-07 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| ES2988683T3 (es) | 2017-06-14 | 2024-11-21 | Adc Therapeutics Sa | Pautas posológicas para la administración de un CAF anti-CD19 |
| JP7220203B2 (ja) | 2017-08-18 | 2023-02-09 | メドイミューン・リミテッド | ピロロベンゾジアゼピン複合体 |
| MX2020003125A (es) | 2017-09-29 | 2020-10-01 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| WO2019096788A1 (en) | 2017-11-14 | 2019-05-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| TW201929908A (zh) | 2017-12-21 | 2019-08-01 | 美商梅爾莎納醫療公司 | 吡咯并苯并二氮呯抗體共軛物 |
| BR112020013492A2 (pt) | 2018-01-08 | 2020-12-08 | Regeneron Pharmaceuticals, Inc. | Esteroides e conjugados de anticorpo dos mesmos |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| CN112119098B (zh) | 2018-03-28 | 2025-06-24 | 田边三菱制药株式会社 | cMET单克隆结合剂的药物缀合物及其用途 |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| AU2019262953B2 (en) | 2018-04-30 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof |
| KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
| CA3100021A1 (en) | 2018-05-17 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US11084801B2 (en) | 2018-05-29 | 2021-08-10 | Intocell, Inc. | Benzodiazepine derivatives and uses thereof |
| US12274898B2 (en) | 2018-10-31 | 2025-04-15 | Intocell, Inc. | Substituted benzodiazepines as antibody-drug conjugates |
| US12209180B2 (en) | 2018-11-20 | 2025-01-28 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists |
| IL318210A (en) | 2018-12-21 | 2025-03-01 | Regeneron Pharma | Rifampicin analogs and their antibody-drug conjugates |
| KR20210106467A (ko) | 2018-12-21 | 2021-08-30 | 리제너론 파마슈티칼스 인코포레이티드 | 튜불리신 및 단백질-튜불리신 접합체 |
| PH12021551629A1 (en) | 2019-01-08 | 2022-06-06 | Regeneron Pharma | Traceless linkers and protein-conjugates thereof |
| CN113727757A (zh) | 2019-02-21 | 2021-11-30 | 瑞泽恩制药公司 | 使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法 |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| CN110078749B (zh) * | 2019-06-04 | 2021-01-01 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 3a，3a′-双呋喃[2,3-b]吲哚啉类化合物、制备方法、药物组合物及应用 |
| MX2022002886A (es) | 2019-09-16 | 2022-04-06 | Regeneron Pharma | Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet. |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| US20240123081A1 (en) | 2019-10-25 | 2024-04-18 | Medimmune, Llc | Branched moiety for use in conjugates |
| WO2021137646A1 (ko) | 2019-12-31 | 2021-07-08 | 주식회사 레고켐바이오사이언스 | 피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체 |
| CN115348874A (zh) | 2020-01-24 | 2022-11-15 | 里珍纳龙药品有限公司 | 蛋白质-抗病毒化合物偶联物 |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| IL297027B2 (en) | 2020-04-16 | 2025-08-01 | Regeneron Pharma | Antibody-drug conjugates prepared using diels-alder conjugation methods |
| CA3185601A1 (en) | 2020-06-24 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| CA3183184A1 (en) | 2020-07-13 | 2022-01-20 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| KR20230070337A (ko) | 2020-09-14 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | Glp1 펩티도미메틱을 포함하는 항체-약물 접합체 및 이의 용도 |
| MX2023004434A (es) | 2020-10-22 | 2023-05-08 | Regeneron Pharma | Anticuerpos anti-fgfr2 y metodos para usarlos. |
| AU2022320713A1 (en) | 2021-07-28 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Protein-antiviral compound conjugates |
| WO2023129518A1 (en) | 2021-12-29 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| JP2025502147A (ja) | 2022-01-12 | 2025-01-24 | リジェネロン ファーマシューティカルズ，インク． | タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用 |
| KR20240135631A (ko) | 2022-01-14 | 2024-09-11 | 리제너론 파마슈티칼스 인코포레이티드 | 베루카린 a 유도체 및 이의 항체 약물 접합체 |
| JP2025512735A (ja) | 2022-03-11 | 2025-04-22 | リジェネロン ファーマシューティカルズ，インク． | Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用 |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| AU2023310999A1 (en) | 2022-07-21 | 2025-01-23 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
| KR20250128394A (ko) | 2022-11-30 | 2025-08-27 | 리제너론 파마슈티칼스 인코포레이티드 | Tlr7 작용제 및 이의 항체-약물-접합체 |
| KR20250133813A (ko) | 2022-12-21 | 2025-09-08 | 리제너론 파마슈티칼스 인코포레이티드 | Adc 접합을 위한 토포이소머라아제 i 억제제의 전구약물 및 이의 사용 방법 |
| WO2024168199A1 (en) | 2023-02-09 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates via inverse electron demand diels-alder reactions |
| AU2024256916A1 (en) | 2023-04-18 | 2025-12-04 | Astrazeneca Ab | Conjugates comprising cleavable linkers |
| WO2024229105A1 (en) | 2023-05-02 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| WO2025096921A1 (en) | 2023-11-03 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
| WO2025117727A1 (en) | 2023-11-29 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361742A (en) | 1964-12-07 | 1968-01-02 | Hoffmann La Roche | 5-oxo-1h-pyrrolo-[2, 1-c][1, 4]-benzodiazepin-2-crylamides |
| US3523941A (en) | 1967-03-06 | 1970-08-11 | Hoffmann La Roche | Benzodiazepine compounds and process for their preparation |
| US3524849A (en) | 1967-10-27 | 1970-08-18 | Hoffmann La Roche | Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein |
| IL33558A (en) | 1968-12-30 | 1973-10-25 | Fujisawa Pharmaceutical Co | Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production |
| JPS4843755B1 (enExample) | 1969-06-26 | 1973-12-20 | ||
| FR2027356A1 (en) | 1968-12-30 | 1970-09-25 | Fujisawa Pharmaceutical Co | Benzodiazepinone antibiotics |
| JPS5382792U (enExample) | 1976-12-10 | 1978-07-08 | ||
| JPS585916B2 (ja) | 1977-12-27 | 1983-02-02 | 株式会社ミドリ十字 | 新規ベンゾジアゼピン系化合物 |
| JPS5615289A (en) | 1979-07-17 | 1981-02-14 | Green Cross Corp:The | Novel benzodiazepinnbased compound 3 |
| JPH0353356Y2 (enExample) | 1981-02-06 | 1991-11-21 | ||
| CA1184175A (en) | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
| CA1173441A (en) | 1981-02-27 | 1984-08-28 | Hoffmann-La Roche Limited | Imidazodiazepines |
| CA1185602A (en) | 1981-02-27 | 1985-04-16 | Emilio Kyburz | Imidazodiazepines |
| JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質ｄｃ−８１およびその製造法 |
| JPS58180487U (ja) | 1982-05-28 | 1983-12-02 | 松下電工株式会社 | 光線式報知器の組立体 |
| US4427588A (en) | 1982-11-08 | 1984-01-24 | Bristol-Myers Company | Process for conversion of oxotomaymycin to tomaymycin |
| US4427587A (en) | 1982-11-10 | 1984-01-24 | Bristol-Myers Company | Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B |
| JPS59152329A (ja) | 1983-02-17 | 1984-08-31 | Green Cross Corp:The | 局所障害抑制剤 |
| JPS59190992A (ja) * | 1983-04-12 | 1984-10-29 | Green Cross Corp:The | ベンゾジアゼピン誘導体 |
| FR2586683B1 (fr) | 1985-08-29 | 1988-07-01 | Centre Nat Rech Scient | Nouveaux derives de neothramycine, leur procede de preparation et leur application en tant que medicaments |
| JP2660201B2 (ja) | 1988-08-05 | 1997-10-08 | 塩野義製薬株式会社 | 新規ピロロ［１，４］ベンゾジアゼピン誘導体および老人性痴呆薬 |
| FR2676230B1 (fr) | 1991-05-07 | 1993-08-27 | Centre Nat Rech Scient | Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant. |
| GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
| FR2696176B1 (fr) | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| GB9316162D0 (en) | 1993-08-04 | 1993-09-22 | Zeneca Ltd | Fungicides |
| US20020113770A1 (en) | 1998-07-08 | 2002-08-22 | Joseph M. Jacobson | Methods for achieving improved color in microencapsulated electrophoretic devices |
| ATE320436T1 (de) | 1998-08-27 | 2006-04-15 | Spirogen Ltd | Dimere pyrrolobenzodiazepine |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| US6660742B2 (en) | 2000-09-19 | 2003-12-09 | Taiho Pharmaceutical Co. Ltd. | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| US6660856B2 (en) | 2002-03-08 | 2003-12-09 | Kaohsiung Medical University | Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| US20040138269A1 (en) | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| CA2520898C (en) | 2003-03-31 | 2009-10-20 | Council Of Scientific And Industrial Research | Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP1675857B1 (en) | 2003-10-22 | 2011-07-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| ES2456325T3 (es) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| PT2270010E (pt) | 2004-03-01 | 2012-03-12 | Spirogen Ltd | Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2 |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404574D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| DE102004010943A1 (de) | 2004-03-03 | 2005-09-29 | Degussa Ag | Verfahren zur Herstellung von N-geschützten 4-Ketprolinderivaten |
| WO2005085260A1 (en) | 2004-03-09 | 2005-09-15 | Spirogen Limited | Pyrrolobenzodiazepines |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| JP2006203186A (ja) | 2004-12-24 | 2006-08-03 | Showa Denko Kk | 熱電半導体合金の製造方法および熱電変換モジュールならびに熱電発電装置 |
| ES2477765T3 (es) | 2005-04-19 | 2014-07-17 | Seattle Genetics, Inc. | Agentes de unión al anti-cd70 humanizado y usos de los mismos |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| PT1879901E (pt) | 2005-04-21 | 2010-03-29 | Spirogen Ltd | Pirrolobenzodiazepinas |
| US8637664B2 (en) | 2005-10-05 | 2014-01-28 | Spirogen Sarl | Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| US20070154906A1 (en) | 2005-10-05 | 2007-07-05 | Spirogen Ltd. | Methods to identify therapeutic candidates |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| US8460667B2 (en) | 2006-07-18 | 2013-06-11 | Sanofi | EPHA2 receptor antagonist antibodies |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| WO2008050140A2 (en) | 2006-10-27 | 2008-05-02 | Spirogen Limited | Compounds for treatment of parasitic infection |
| EP2609932B1 (en) | 2006-12-01 | 2022-02-02 | Seagen Inc. | Variant target binding agents and uses thereof |
| US8465883B2 (en) | 2007-07-11 | 2013-06-18 | The Regents Of The University Of California | Nanostructured polymer membranes for proton conduction |
| ES2435779T3 (es) | 2007-07-19 | 2013-12-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico |
| GB0722087D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Polyamides |
| GB0722088D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US20090310707A1 (en) | 2008-06-17 | 2009-12-17 | Jung-Fu Cheng | Transmitter and method for transmitting soft pilot symbols in a digital communication system |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CN105198908B (zh) | 2009-02-05 | 2019-12-24 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| EP2480230A4 (en) | 2009-09-24 | 2015-06-10 | Seattle Genetics Inc | DR5 Ligand-HEILMITTELKONJUGATE |
| WO2011100227A1 (en) | 2010-02-09 | 2011-08-18 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
| CN102933236B (zh) | 2010-04-15 | 2014-10-08 | 斯皮罗根有限公司 | 吡咯并苯二氮卓类及其结合物 |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| PT2675480T (pt) | 2011-02-15 | 2019-04-15 | Immunogen Inc | Métodos para preparação de conjugados |
| CN103987718A (zh) | 2011-09-20 | 2014-08-13 | 斯皮罗根有限公司 | 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓 |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| AU2012322933B2 (en) | 2011-10-14 | 2017-02-02 | Medimmune Limited | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| CN103998450B (zh) | 2011-10-14 | 2017-03-08 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓 |
| CN103998449A (zh) | 2011-10-14 | 2014-08-20 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓 |
| WO2013055987A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| EP2855482B1 (en) | 2012-04-30 | 2017-03-01 | MedImmune Limited | Pyrrolobenzodiazepines |
| NZ701478A (en) | 2012-04-30 | 2016-08-26 | Medimmune Ltd | Pyrrolobenzodiazepines |
| JP2015523380A (ja) | 2012-07-09 | 2015-08-13 | ジェネンテック， インコーポレイテッド | 抗ｃｄ７９ｂ抗体を含む免疫複合体 |
| PE20150615A1 (es) | 2012-07-09 | 2015-05-28 | Genentech Inc | Inmunoconjugados que comprenden un anticuerpo anti-cd22 ligado a una pirrolobenzodiazepina |
| EP2879708A4 (en) | 2012-08-02 | 2016-03-16 | Genentech Inc | ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| RS58921B1 (sr) | 2012-10-12 | 2019-08-30 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
| CA2887896A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
| PT2906253T (pt) | 2012-10-12 | 2018-11-05 | Medimmune Ltd | Conjugados de anticorpo anti-psma de pirrolobenzodiazepina |
| HRP20182129T1 (hr) | 2012-10-12 | 2019-02-08 | Adc Therapeutics Sa | Konjugati protutijelo - pirolobenzodiazepin |
| HRP20180945T1 (hr) | 2012-10-12 | 2018-08-10 | Adc Therapeutics Sa | Konjugati protutijelo-pirolobenzodiazepin |
| LT2906251T (lt) | 2012-10-12 | 2017-12-11 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-cd22 antikūno konjugatai |
| CA2885305C (en) | 2012-10-12 | 2019-11-12 | Spirogen Sarl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| CN104703630A (zh) | 2012-10-12 | 2015-06-10 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| WO2014096368A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| JP6527466B2 (ja) | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
| PL2958944T3 (pl) | 2013-02-22 | 2019-09-30 | Abbvie Stemcentrx Llc | Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania |
| NZ710746A (en) | 2013-03-13 | 2018-11-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| KR102066319B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| US20160256561A1 (en) | 2013-10-11 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| JP6681838B2 (ja) | 2013-12-16 | 2020-04-15 | ジェネンテック， インコーポレイテッド | ペプチド模倣薬化合物及びその抗体−薬剤複合体 |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
-
2012
- 2012-10-12 CN CN201280062290.1A patent/CN103998450B/zh not_active Expired - Fee Related
- 2012-10-12 JP JP2014535097A patent/JP6170497B2/ja not_active Expired - Fee Related
- 2012-10-12 SG SG11201401021TA patent/SG11201401021TA/en unknown
- 2012-10-12 WO PCT/EP2012/070233 patent/WO2013053873A1/en not_active Ceased
- 2012-10-12 EA EA201490535A patent/EA028457B1/ru unknown
- 2012-10-12 MX MX2014004557A patent/MX341523B/es active IP Right Grant
- 2012-10-12 US US14/351,173 patent/US9399073B2/en not_active Expired - Fee Related
- 2012-10-12 CA CA2850103A patent/CA2850103C/en not_active Expired - Fee Related
- 2012-10-12 KR KR1020147012411A patent/KR101891859B1/ko not_active Expired - Fee Related
- 2012-10-12 BR BR112014008888A patent/BR112014008888A2/pt not_active Application Discontinuation
- 2012-10-12 EP EP12772782.4A patent/EP2751111B1/en not_active Not-in-force
- 2012-10-12 AU AU2012322934A patent/AU2012322934B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014528467A (ja) | 2014-10-27 |
| US9399073B2 (en) | 2016-07-26 |
| MX341523B (es) | 2016-08-24 |
| EP2751111B1 (en) | 2017-04-26 |
| EA028457B1 (ru) | 2017-11-30 |
| WO2013053873A1 (en) | 2013-04-18 |
| US20140274907A1 (en) | 2014-09-18 |
| EP2751111A1 (en) | 2014-07-09 |
| CA2850103A1 (en) | 2013-04-18 |
| KR20140099449A (ko) | 2014-08-12 |
| CA2850103C (en) | 2019-09-10 |
| CN103998450B (zh) | 2017-03-08 |
| BR112014008888A2 (pt) | 2017-04-18 |
| AU2012322934A1 (en) | 2014-05-29 |
| AU2012322934B2 (en) | 2016-09-08 |
| JP6170497B2 (ja) | 2017-07-26 |
| KR101891859B1 (ko) | 2018-08-24 |
| EA201490535A1 (ru) | 2014-09-30 |
| CN103998450A (zh) | 2014-08-20 |
| MX2014004557A (es) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201401021TA (en) | Pyrrolobenzodiazepines | |
| DK3424953T3 (en) | Terapeutiske antistoffer | |
| DK2691417T4 (en) | Antistof fc-varianter | |
| ZA201407759B (en) | Pyrrolobenzodiazepines | |
| ZA201408043B (en) | Pyrrolobenzodiazepines | |
| EP2755962A4 (en) | AZAINDAZOLES | |
| EP2715659A4 (en) | ABOUT FEED | |
| EP2754063A4 (en) | EXTENSIBILITY OF THE SMB2 PROTOCOL | |
| EP2723631A4 (en) | QUADFOILER | |
| EP2776444A4 (en) | dihydropteridinones | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| EP2695208A4 (en) | MICRO-THERMOCOUPLE | |
| DK2770906T3 (en) | Applanationstonometer | |
| GB2512771B (en) | Ablutionary fitting | |
| GB201101727D0 (en) | Obuoy | |
| GB201100001D0 (en) | TidySqueeze2 | |
| AU5171P (en) | Sunparamiho Mandevilla xamabilis | |
| AU5026P (en) | Goldstrike Agapanthus inapertus | |
| AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
| AU5031P (en) | BESYS Beschorneria yuccoides | |
| AP00723S1 (en) | Autorickshaw | |
| GB201109631D0 (en) | Better picniks | |
| GB201102519D0 (en) | Mirrorcane | |
| GB201101143D0 (en) | Post-reference | |
| GB201102443D0 (en) | Atompower |